Lymphoma-associated haemophagocytic syndrome (LAHS) accounts for most cases of secondary haemophagocytic syndrome (HS) and has been extensively described in Asian populations. However, little is known about the epidemiology of LAHS in Western countries. We herein report a case series of 71 LAHS patients in which the lymphomas were mainly of the aggressive type. Diagnoses included non-Hodgkin B cell lymphoma (46Á5%) including human herpes virus 8-associated non-Hodgkin lymphoma (12Á7%), T cell lymphoma (28Á2%) and Hodgkin lymphoma (23Á9%). An underlying immunodeficiency was described in 30 patients (42Á3%). Early mortality within the 30 days following HS diagnosis was observed in 26Á8% of cases. The overall survival was estimated at 45Á7% [95% confidence interval, CI (35Á4-59Á0)] at 6 months, and 34Á3% [95% CI (24Á8-47Á4)] at 2 years. Concurrent infection, age over 50 years, ethnicity and etoposide treatment were independently associated with mortality. While it appears that certain types of lymphomas were more prone to trigger HS, LAHS were not restricted to a few types of lymphoma. The overall prognosis was poor, with a particularly high rate of early mortality, highlighting the importance of both early recognition and choice of initial therapeutic management.
Introduction
Haemophagocytic syndrome (HS) is a life-threatening condition, related to inappropriate stimulation and proliferation of cytotoxic lymphocytes and macrophages. The aberrantly activated macrophages extensively phagocytose haematopoietic cells. The diagnosis of HS in adults remains difficult, but the HScore, which has been recently developed and validated among a large cohort of adults with HS (Hejblum et al, 2014) , is a useful diagnostic tool. Commonly, HS is divided into 'primary' and 'secondary' forms. 'Primary' HS pertains to infants, children and adolescents with predisposing inherited immune deficiencies. Secondary forms of HS may occur at any age and are associated with a vast array of disorders including malignancies, infections and autoimmune diseases. Malignancy is the most common trigger identified in adults with HS (Buyse & De Labarthe, 2010; Rivi ere et al, 2014) . Lymphoid malignancies seem to be more frequently associated with secondary HS, as it is reported in 20-60% of patients in various case series (Ishii et al, 2007; Buyse & De Labarthe, 2010; Ramos-casals et al, 2014; Rivi ere et al, 2014) .
Lymphoma-associated HS (LAHS) has been extensively described in Asian populations (Han et al, 2007; Ishii et al, 2007; Yu et al, 2013) . However, there might be marked differences between the Asian population and patients treated in occidental countries. Notably, T cell, natural killer (NK)/T cell lymphomas and intravascular large B cell lymphomas are very frequent in Asian populations, but are extremely rare neoplasms in the Western world Ponzoni et al, 2007) . Therefore, genetic and environmental factors may impact the incidence and the characteristics of LAHS.
In Western countries, various types of lymphoma associated with HS, including B cell lymphomas, T cell lymphomas and Hodgkin lymphomas, have been reported in small case series (Majluf-cruz et al, 1998; Allory et al, 2001; Klimkowska et al, 2011) . Poor survival has been reported (Ishii et al, 2007; Rivi ere et al, 2014) , as well as a frequent association with an underlying immunodeficiency condition, such as human immunodeficiency virus (HIV) infection or immunosuppressive drugs (Buyse & De Labarthe, 2010; Fardet et al, 2010) . However, due to their small patient size and their heterogeneity in study design, currently reported studies do not depict an accurate clinical picture of LAHS in Western populations. We therefore conducted a retrospective, multicentre study over a 7-year period, which aimed to describe the clinical, biological and therapeutic-related characteristics of adults from Western populations with LAHS. We also aimed to determine the overall survival and the mortality-associated factors within this specific population.
Methods

Patients
The present cohort is a nested cohort from the study reported by Rivi ere et al (2014) and included patients with HS confirmed by four experts and lymphoma confirmed by a senior cytologist and/or pathologist using immunochemistry as required. Between June and November 2012, the four experts retrospectively reviewed the medical charts and confirmed the diagnosis of HS in 162 out of 312 pre-selected patients (Rivi ere et al, 2014) . Among the 162 patients, 92 were diagnosed with a haematological malignancy, and of these, 74 were determined to be lymphoma. Three patients were excluded because of missing data. The lymphoma was considered to be concomitant with the HS when it was diagnosed within the two months of HS diagnosis.
The clinical and biological data were retrospectively reviewed according to a pre-established labelled chart including: Hscore, Henter score, age at lymphoma diagnosis and at HS diagnosis, performance status at lymphoma diagnosis, lymphoma characteristics (lactate dehydrogenase, albumin, organ involved, Ann Arbor stage, International Prognostic Index (IPI) or Hasenclever International Prognosis Score (IPS), biopsy completed, treatment prescribed for the lymphoma, date of relapse, outcome and type of underlying immunodeficiency. Concurrent infection was defined by any infection documented during the hospitalization for the HS.
Pathological, immunophenotypic and cytogenetic analyses
Pathology and immunohistochemistry reports were reviewed for each patient. All the pathology reports were established by experts from the three academic centres involved in the study. All histology and immunochemistry assessments were performed at the time of lymphoma diagnosis. For B cell lymphoma, the immunohistochemical stains reviewed were CD20, CD5, BCL2, BCL6, CD10 and MUM1, CD30. Diffuse large B cell lymphoma cases were divided by origin of tumour cells as germinal centre B cell-like (GCB) or activated B-cell-like (ABC), based on immunohistochemical expression of CD10, BCL6 or MUM1 according to Hans et al (2004) . For T cell lymphoma, the immunohistochemical stains reviewed were CD2, CD3, CD5, CD4, CD8, CD56, CD30, ALK, CXCL13 and cytotoxic markers, such as Granzyme B or TiA1. For Hodgkin lymphoma (HL), the immunohistochemical stains reviewed were CD30, CD15 and CD20. Infection by Epstein-Barr Virus (EBV) was assessed either by Latent Membrane Protein (LMP) immunohistochemical staining or by in situ hybridization (ISH) on fixed tissues, using EBV-encoded RNA detection (EBER). Specific probes human herpes virus 8 (HHV8) was detected on fixed tissues by immunochemistry using latent-associated nuclear antigen (LANA) protein antibody. For B cell lymphoma, MYC translocation by cytogenetic or fluorescence in situ hybridization (FISH) results was reviewed when available.
Primary endpoint and statistical analysis
In the descriptive analysis, quantitative variables were reported as medians with interquartile range (IQR) and qualitative variables as number with percentage (n, %). Followup started at the date of HS diagnosis and ended at the date of death or date of last examination. The median follow-up was calculated using reverse censoring. Overall survival (OS) was calculated from the date of HS diagnosis to date of death from any cause. When the latter date was not reached, the date was censored at the time of the last follow-up evaluation. Survival functions were estimated by the Kaplan-Meier method. Confidence intervals were calculated using log-transformation for survival analysis. Survival among subgroups was compared using a log-rank test.
The primary endpoint was defined as death from any cause. In order to identify predictors of death, a Cox proportional hazards regression analysis was performed. For the multivariate model, variables were entered into a Cox proportional hazards regression model with a stepwise variable elimination procedure. The results were reported with hazard Improving Prognosis in LAHS ª 2018 British Society for Haematology and John Wiley & Sons Ltd ratios (HR) and their 95% confidence interval (95%CI). Alpha risk was set at 5% for statistical significance level. Calculations were performed with R (The R Project for Statistical Computing -https://www.r-project.org/).
Results
Hemophagocytic syndrome characteristics
A total of 71 patients who presented with LAHS were studied. The median follow-up was 72Á8 months. The baseline clinical and biological features of patients at the time of HS diagnosis are detailed in Table I . The majority of the patients were male (67Á6%), and the median age at HS diagnosis was 53 years. Although most of the patients were white European (59Á2%), a large proportion had African ethnic origins (either sub-Saharan Africa or north Africa). Splenomegaly, hepatomegaly, superficial and deep lymphadenopathy were commonly found clinical features (77Á5%, 72Á9%, 67Á6% and 71Á4%, respectively). The median leucocytes, haemoglobin and platelet counts were 2Á8 9 10 9 /l, 81 g/l, and 49 9 10 9 /l, respectively. The presence of haemophagocytotic features on bone marrow aspirates was frequent (70Á4%). All cases of HS were considered to be due to lymphoma (at diagnosis or relapse), i.e. none was secondary to an infectious event under chemotherapy. The lymphoma was diagnosed concomitantly with HS in 49 patients (73Á1%) and the medical team in charge correctly established the diagnosis of HS in 68 cases (97Á1%).
Treatment of haemophagocytic syndrome
Fifty-eight patients (81Á7%) received a specific treatment for HS. Among these patients, the median time between HS diagnosis and treatment initiation was 0Á5 days (from 0 to 47 days). Treatments used for HS are detailed in Table II . Of note, 47 patients (81Á0%) were treated with etoposide (with or without corticosteroids) and 9 patients (15Á5%) received corticosteroids alone. Among the untreated patients, the rate of early death (within 30 days after HS diagnosis) was 42% compared to 24Á1% in treated patients (P = 0Á29).
Lymphoma diagnosis
The lymphoma was diagnosed a median of 4 days [IQR (0-13)] after the HS. In 62Á0% of the cases, the diagnosis was established after either a lymph node biopsy or a bone marrow biopsy. Of note, splenectomy led to a lymphoma diagnosis in three patients. At diagnosis, the lymphoma characteristics (detailed in Table III) showed disseminated disease in 95Á5% of cases. Lymph nodes and bone marrow were the most frequently involved sites (67Á7% and 47Á7%, respectively). The lymphomas were mainly aggressive and presented a high IPI (median IPI = 4; median adjusted-age IPI = 3). For HL, the median Hasenclever Index (International Prognostic Score) was 5. Thirty patients (42Á3%) presented an underlying immunodeficiency, of which HIV infection was the most frequent (73Á2%, 22 patients). 
Histological characteristics of lymphoma
Twenty-four patients (33Á8%) had a diagnosis of HHV8-negative B cell non-Hodgkin lymphoma (B-NHL), 9 patients (12Á7%) an HHV8-associated B-NHL (HHV8-NHL), 20 patients (28Á2%) presented a T cell lymphoma and 17 patients (23Á9%) had HL (detailed in Table IV) .
B-NHL.
Fourteen patients had diffuse large B cell lymphoma (DLBCL). According to the Hans algorithm (Hans et al, 2004) , the cell of origin of B cell lymphoma could be specified for 8 patients (6 ABC DLBCL, 2 GCB DLBCL. DLBCL resulted from an indolent lymphoma transformation in 3 patients (2 chronic lymphocytic leukaemia, 1 follicular lymphoma). Intravascular B cell lymphomas occurred in 4 patients, of which 2 were of Asian origin. Only one EBVassociated B-NHL was reported.
HHV8-NHL.
Nine patients presented with HHV8-NHL, including 2 primary effusion lymphomas (PEL) and 7 HHV8-associated DLBCL. All the patients were positive for HIV, and Castleman disease was co-diagnosed in all cases.
T -NHL. Twenty patients (28Á2%) presented with T cell lymphoma, with T cell lymphoma not otherwise specified (NOS) being the predominant. NK/T cell lymphoma was diagnosed in 4 patients. Only one patient had a typical presentation with nasal involvement, while the others presented extra-nasal involvement. Three patients presented with anaplastic T cell lymphoma. Of note, when available, staining for cytotoxic markers, such as Granzyme B or TIA1, was always positive (10/10) among the T cell lymphomas. None were associated with EBV or Human T-lymphotropic virus type 1. T cell lymphoma, not otherwise specified 11 (55Á0%) Natural killer/T cell lymphoma 4 (20Á0%) Anaplastic T cell lymphoma 3 (15Á0%) Angioimmunoblastic T cell lymphoma 1 (5Á0%) Transformed mycosis fungoides 1 (5Á0%) Hodgkin lymphoma, n = 17 EBV-associated 13 (81Á3%) HIV positive 9 (52Á9%) Large cell lymphoma (without more specificities), n = 1 (1Á4%) EBV, Epstein-Barr virus; HHV8, human herpes virus 8; HIV, human immunodeficiency virus.
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Hl. Seventeen patients, of whom 9 were HIV-positive, presented a HL. EBV testing was available for 16 patients and was positive in 13 patients (81Á3%).
Lymphoma treatment
Nine patients (12Á7%) did not receive a specific treatment for lymphoma because of an uncontrolled HS, which caused an early death. The remaining 62 patients were treated for their lymphoma and 32 (58Á2%) were in complete remission after a first line regimen. Some data was missing for seven patients.
Survival and factors associated with survival
At last follow-up, 50 patients (70Á4%) had died and 19 patients (26Á8%) had achieved complete remission. Very early mortality, defined as death within 15 days of HS diagnosis, was observed in 11 patients (15Á5%), whereas early mortality, defined as death within 30 days of HS diagnosis, was observed in 19 patients (26Á8%).
The overall survival (OS) was estimated at 45Á7% [95% CI (35Á4-59Á0)] and 34Á3% [95% CI (24Á8-47Á4]) at 6 and 24 months, respectively. The estimated OS at 6 months was 66Á7% [95% CI (42Á0-100Á0)], 52Á9% [95% CI (33Á8-82Á9)], 37Á5% [95% CI (22Á4-62Á9)] and 40Á0% [95% CI (23Á4-68Á4)] for HHV8-NHL, HL, B-NHL and T cell lymphoma, respectively (Fig 1 and Figures S1 and S2 , using a log scale to represent the time axis). The OS stayed stable or decreased slightly between 12 and 24 months for the HHV8-NHL, HL and the B-NHL (66,7%, 47,1% and 29,2% at 24 months respectively), indicating the development of a plateau. However, OS for T cell lymphoma declined, from 25% [95% CI (11Á7-53Á4)] at 12 months to 15% [95% CI (5Á3-42Á6)] at 24 months. The OS was lower for patients with T-NHL compared to HL (P = 0Á04) and to HHV8-NHL (P < 0Á01) but not to B-NHL (P = 0Á73). The OS was also lower for patients with B-NHL compared to HHV8-NHL (P = 0Á03). The univariate Cox model analysis is displayed in 
Discussion
The present study provided an extensive and detailed clinical picture of a large cohort of LAHS patients in a Western adult population. Notably, we showed that while T-NHL is the leading cause of LAHS in Asia (Yu et al, 2013; Li et al, 2015) , B-NHL was more represented in this Western population. However, compared to the epidemiology of lymphomas in Western countries (Smith et al, 2015) , T cell lymphoma and HLs were overrepresented, as they accounted for 50% of all the lymphomas. Moreover, some B cell lymphoma subtypes were remarkably absent from our cohort, such as Burkitt lymphomas and low-grade B cell lymphomas. Interestingly, a high proportion of B cell lymphomas were associated with the presence of an oncogenic virus (HHV8 or EBV). Among the T cell lymphomas, angioimmunoblastic lymphomas were under-represented. Thus, it appears that not all types of lymphomas are disposed to trigger HS. Almost all T cell lymphoma patients in our study expressed cytotoxic markers, indicating that cytotoxic T cell lymphomas are more prone to induce HS. This suggests that lymphoma cell of origin may drive the risk of secondary HS by its ability to secrete inflammatory cytokines (T cell lymphoma), or to present antigens that can activate a cytotoxic T cell response (viral-associated B cell lymphoma or ABC DLBCL). In our cohort, one of the most striking findings was the very high rate of early mortality (27%) along with the high rate of patients who did not receive any HS-specific treatment (18%), despite the fact that the diagnosis was Table V . Univariate and multivariate analysis of factors associated with overall survival. confirmed by the medical team in almost all the cases. One can assume that some medical teams might have considered some patients too severe or too old to receive any strong immunosuppressive drugs. On the other hand, HS early recognition and specific treatment initiation appears to be a key factor in the management of LAHS. Given our results, we believe treatment by etoposide should be started as soon as the diagnosis of HS is confirmed. The presence of concurrent infection was independently associated with mortality, and HS is known to induce a non-specific T cell activation leading to an exhausted T cell response that may favour viral or intracellular infectious agent reactivation (Boisseau et al, 2015) . HS is also responsible for a prolonged myelosuppression that may favour bacterial and fungal infection (Sung et al, 2002) . With this, we can speculate that the presence of sepsis may reflect the severity of HS or a long-standing HS.
As sepsis features could mimic HS clinical features, sepsis should always be considered and wide spectrum antibiotics should be initiated early. However, concurrent infection should not delay HS-specific treatment. Additionally, although low, the 6-month OS, estimated at 45Á7% [95% CI (35Á4-59Á0)], appeared to be better than that previously observed in smaller cohorts (Schram et al, 2016) . HHV8-NHL cases had the best prognosis in our cohort. The group included two PEL patients that died soon after diagnosis, and 7 DLBCL patients that had HHV8+ Castleman disease; the latter has been shown to be sometimes polyclonal and very sensitive to rituximab (Gerard et al, 2012; Oksenhendler et al, 2013) . The 6-month OS in patients with HLassociated HS was estimated at 52Á9%, a rate comparable with previous studies of high IPI HL (Hasenclever & Diehl, 1998) . HS therefore does not seem to impact HL prognosis, but we can also speculate that the Hasenclever IPS model takes into account the impact of HS by putting a negative prognostic value to cytopenias and low albumin level. Interestingly, B-NHL associated HS had the same short-term prognosis as T cell lymphoma-associated HS. Nevertheless, long-term survival analysis of these 2 groups demonstrated that, unlike B-NHL, mortality after 1 year is not uncommon with T cell lymphoma. Therefore, while T cell lymphomaassociated HS had a particularly poor prognosis, probably secondary to the inherently poor prognosis of the T cell lymphoma, the severity of HS can severely impact the prognosis of B-NHL. Thus, the long-term lymphoma prognosis may be comparable to a similar lymphoma not associated with HS, once the initial and crucial early period is overcome. It then appears that the long-term prognosis improvement of lymphoma associated with HS may be accomplished through the optimization of management during the initial HS diagnostic period. In our cohort, patients treated with etoposide seemed to have a better outcome at 30 days. We suggest that etoposide should be included in the initial chemotherapy regimen of LAHS until evaluation of novel promising agents for HS in the context of LAHS, such as JAK inhibitors, alemtuzumab or anti-interferon c antibody (Strout et al, 2010; Jordan et al, 2015; Maschalidi et al, 2016) .
Of note, the presence of an underlying immunodeficiency, although non-significant in the multivariate analysis, was associated with a better outcome in the univariate analysis. Indeed, immunodeficient patients were mainly affected with HL and HHV8-NHL.
While our study is inherently limited by its retrospective design, it is strengthened by some assets: the HS diagnosis, which can sometimes be difficult, was centralized and established by a panel of 4 experts, and the patients were followed in tertiary centres and had an extensive clinical and biological work up. Moreover, and to our knowledge, this is the largest cohort of LAHS cases, a very rare entity, established in a Western country to date.
In conclusion, from our multicentre cohort based in a Western country, we described that a wide spectrum of lymphomas, including numerous B cell lymphomas, could cause HS, although it appears that certain lymphomas are more prone to trigger an HS. The prognosis is poor with a particularly high rate of early mortality in non-etoposide treated patients. Improving the early management of LAHS appears crucial to improve the overall survival rate of affected patients.
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